Time-Efficacy Relationship of Semaglutide in the Treatment of Type 2 Diabetes Mellitus: A Model-Based Meta-Analysis.

Zhang K, Zhao A, Wang Z, Ye K, Xu Z, Gong X, Zhu G

Clinical pharmacokinetics16 Nov 2024

PMID39549228DOI10.1007/s40262-024-01449-1PepBankPUB-39549228

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanSystematic reviewEfficacy outcome
In a model-based meta-analysis of semaglutide trials in type 2 diabetes, the simulated maximum HbA1c change was -1.58% with 0.5 mg.
In plain wordsIn a model built from trials in type 2 diabetes, 0.5 mg semaglutide was predicted to lower HbA1c by at most 1.58%.
Peptide
Semaglutide
Outcome
DecreaseMaximum HbA1c efficacy (Emax) at 0.5 mg
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 mg · subcutaneousAs given in this study (human).
Measurements
Emax HbA1c change
−1.58%
0.5 mg
Source sentences
Summary
Simulation of the typical efficacy at the different doses yielded a maximum efficacy of -1.58% with 0.5 mg
2 context sentences(design, population, supporting numbers)
Summary · context
Our objective was to quantify the efficacy of subcutaneous once-weekly semaglutide in treating type 2 diabetes mellitus (T2DM) over time.
Summary · context
Based on a literature search of the PubMed, Embase, Cochrane, and Web of Science databases, a modified maximum effect (E_max) model including rebound effects was built using model-based meta-analysis with change from baseline in glycated hemoglobin as the efficacy endpoint.
Report a problemFND-3954922801
02HumanSystematic reviewEfficacy outcome
In a model-based meta-analysis of semaglutide trials in type 2 diabetes, the simulated maximum HbA1c change was -1.87% with 1 mg.
In plain wordsIn a model built from trials in type 2 diabetes, 1 mg semaglutide was predicted to lower HbA1c by at most 1.87%.
Peptide
Semaglutide
Outcome
DecreaseMaximum HbA1c efficacy (Emax) at 1 mg
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1 mg · subcutaneousAs given in this study (human).
Measurements
Emax HbA1c change
−1.87%
1 mg
Source sentences
Summary
a maximum efficacy of -1.87% with 1 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
Our objective was to quantify the efficacy of subcutaneous once-weekly semaglutide in treating type 2 diabetes mellitus (T2DM) over time.
Summary · context
Based on a literature search of the PubMed, Embase, Cochrane, and Web of Science databases, a modified maximum effect (E_max) model including rebound effects was built using model-based meta-analysis with change from baseline in glycated hemoglobin as the efficacy endpoint.
Report a problemFND-3954922802
03HumanSystematic reviewEfficacy outcome
In a model-based meta-analysis of semaglutide trials in type 2 diabetes, the model found no evidence of a placebo effect with semaglutide.
In plain wordsIn a model built from semaglutide trials in type 2 diabetes, no placebo effect was found.
Peptide
Semaglutide
Outcome
No significant changePlacebo effect in semaglutide trials
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
There was no evidence of a placebo effect with semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Our objective was to quantify the efficacy of subcutaneous once-weekly semaglutide in treating type 2 diabetes mellitus (T2DM) over time.
Summary · context
Based on a literature search of the PubMed, Embase, Cochrane, and Web of Science databases, a modified maximum effect (E_max) model including rebound effects was built using model-based meta-analysis with change from baseline in glycated hemoglobin as the efficacy endpoint.
Report a problemFND-3954922803
04HumanSystematic reviewEfficacy outcome
In a model-based meta-analysis of semaglutide trials in type 2 diabetes, the HbA1c effect of the other doses became more significant over time.
In plain wordsIn a model built from semaglutide trials in type 2 diabetes, the effect of the other doses grew with time.
Peptide
Semaglutide
Outcome
DecreaseEfficacy over time
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
The efficacy of other doses became more significant over time
2 context sentences(design, population, supporting numbers)
Summary · context
Our objective was to quantify the efficacy of subcutaneous once-weekly semaglutide in treating type 2 diabetes mellitus (T2DM) over time.
Summary · context
Based on a literature search of the PubMed, Embase, Cochrane, and Web of Science databases, a modified maximum effect (E_max) model including rebound effects was built using model-based meta-analysis with change from baseline in glycated hemoglobin as the efficacy endpoint.
Report a problemFND-3954922804
05HumanSystematic reviewEfficacy outcome
In a model-based meta-analysis of semaglutide trials in type 2 diabetes, a rebound effect appeared after maximum efficacy, at a rate of 0.018.
In plain wordsIn a model built from semaglutide trials in type 2 diabetes, the effect partly faded again after reaching its peak.
Peptide
Semaglutide
Outcome
MixedRebound effect after maximum efficacy
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Rebound rate
0.018
after maximum efficacy
Source sentences
Summary
a rebound effect was observed after maximum efficacy, at a rate of 0.018.
2 context sentences(design, population, supporting numbers)
Summary · context
Our objective was to quantify the efficacy of subcutaneous once-weekly semaglutide in treating type 2 diabetes mellitus (T2DM) over time.
Summary · context
Based on a literature search of the PubMed, Embase, Cochrane, and Web of Science databases, a modified maximum effect (E_max) model including rebound effects was built using model-based meta-analysis with change from baseline in glycated hemoglobin as the efficacy endpoint.
Report a problemFND-3954922805
06HumanSystematic reviewOther
In a model-based meta-analysis of semaglutide trials in type 2 diabetes, Emax was influenced by the proportion of males and ET50 by baseline values.
In plain wordsIn a model built from semaglutide trials in type 2 diabetes, the share of men and the starting HbA1c shaped the predicted effect.
Peptide
Semaglutide
Outcome
Not applicableCovariates of Emax and ET50
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
E_max and ET₅₀ were influenced by the proportion of males and the baseline values, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Our objective was to quantify the efficacy of subcutaneous once-weekly semaglutide in treating type 2 diabetes mellitus (T2DM) over time.
Summary · context
Based on a literature search of the PubMed, Embase, Cochrane, and Web of Science databases, a modified maximum effect (E_max) model including rebound effects was built using model-based meta-analysis with change from baseline in glycated hemoglobin as the efficacy endpoint.
Report a problemFND-3954922806
07HumanSystematic reviewEfficacy outcome
In a model-based meta-analysis of semaglutide trials in type 2 diabetes, six simulated doses showed a dose-dependent efficacy relationship except for 0.4 mg and 0.8 mg.
In plain wordsIn a model built from semaglutide trials in type 2 diabetes, higher doses gave more effect, except at 0.4 mg and 0.8 mg.
Peptide
Semaglutide
Outcome
MixedDose-response of semaglutide efficacy
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.1-2 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
In addition, the six simulated doses (0, 0.1, 0.2, 0.5, 1, and 2 mg) showed a dose-dependent relationship between dose and efficacy except for 0.4 mg and 0.8 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
Our objective was to quantify the efficacy of subcutaneous once-weekly semaglutide in treating type 2 diabetes mellitus (T2DM) over time.
Summary · context
Based on a literature search of the PubMed, Embase, Cochrane, and Web of Science databases, a modified maximum effect (E_max) model including rebound effects was built using model-based meta-analysis with change from baseline in glycated hemoglobin as the efficacy endpoint.
Report a problemFND-3954922807
08HumanSystematic reviewOther
In a model-based meta-analysis of semaglutide trials in type 2 diabetes, a higher dose gave greater efficacy and a faster onset of action.
In plain wordsIn a model built from semaglutide trials in type 2 diabetes, a higher dose was predicted to work more and start sooner.
Peptide
Semaglutide
Outcome
Not applicableEfficacy and onset of action at higher dose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
A higher dose would result in greater efficacy and a faster onset of action.
2 context sentences(design, population, supporting numbers)
Summary · context
Our objective was to quantify the efficacy of subcutaneous once-weekly semaglutide in treating type 2 diabetes mellitus (T2DM) over time.
Summary · context
Based on a literature search of the PubMed, Embase, Cochrane, and Web of Science databases, a modified maximum effect (E_max) model including rebound effects was built using model-based meta-analysis with change from baseline in glycated hemoglobin as the efficacy endpoint.
Report a problemFND-3954922808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.